8-K: Molina Healthcare Revises 2025 Guidance Amid Q3 Earnings

Molina Healthcare, Inc. reported third quarter 2025 financial results, including GAAP EPS of $1.51 and adjusted EPS of $1.84, and revised its full-year 2025 earnings guidance downwards due to higher medical cost trends.

Summary

• GAAP earnings per diluted share for the third quarter of 2025 were $1.51, a 73% decrease year over year from $5.65 in Q3 2024.
• Adjusted earnings per diluted share for the third quarter of 2025 were $1.84, a 69% decrease year over year from $6.01 in Q3 2024.
• Premium revenue for the third quarter of 2025 was approximately $10.8 billion, an increase of 12% year over year.
• Total revenue for the third quarter of 2025 was $11.477 billion, up from $10.340 billion in Q3 2024.
• The consolidated Medical Care Ratio (MCR) for the third quarter of 2025 was 92.6%, an increase from 89.2% in Q3 2024.
• Operating cash flow for the nine months ended September 30, 2025, was an outflow of $237 million, compared to an inflow of $868 million for the same period in 2024.
• The company raised its full-year 2025 premium revenue guidance to approximately $42.5 billion.
• The company revised its full-year 2025 adjusted earnings guidance to approximately $14.00 per diluted share.
• Membership as of September 30, 2025, was approximately 5.6 million, an increase of 30,000 members compared to September 30, 2024.

Sentiment

Score: 3

Explanation: While premium revenue and membership grew, the significant decline in GAAP and adjusted net income, the sharp increase in MCR, the negative operating cash flow, and the downward revision of full-year earnings guidance indicate substantial operational challenges and financial underperformance, particularly in the Marketplace and Medicare segments. The positive outlook for 2026 is preliminary and contingent on addressing current issues.

Positives

• Premium revenue increased by 12% year over year to $10.8 billion in Q3 2025, reflecting recent acquisitions, rate increases, and growth in the company's current footprint.
• Company membership increased by 30,000 members year-over-year to approximately 5.6 million as of September 30, 2025.
• The Medicaid business continues to perform well in a challenging medical cost trend environment, producing strong margins and contributing a gain of $3.52 per diluted share to adjusted earnings in Q3 2025.
• The General and Administrative (G&A) ratio and adjusted G&A ratio for Q3 2025 (6.4% and 6.3% respectively) reflect continued operating discipline.
• Full-year 2025 premium revenue guidance was raised to approximately $42.5 billion.
• New store embedded earnings remain strong at $8.65 per diluted share, indicating future growth potential from newly awarded contracts and recently closed acquisitions.
• The company benefited from share repurchases completed in the third quarter of 2025.

Negatives

• GAAP net income decreased by 73% year over year to $1.51 per diluted share in Q3 2025.
• Adjusted net income decreased by 69% year over year to $1.84 per diluted share in Q3 2025.
• The consolidated Medical Care Ratio (MCR) increased to 92.6% in Q3 2025 from 89.2% in Q3 2024, indicating higher medical costs.
• The Marketplace business experienced significant underperformance, contributing a loss of $1.68 per diluted share to adjusted earnings in Q3 2025, driven by much higher utilization relative to risk adjustment revenue (MCR of 95.6%).
• The Medicare business also contributed to the loss, reflecting higher utilization among high-acuity members, particularly for long-term services and supports and pharmacy (MCR of 93.6%).
• Operating cash flow for the nine months ended September 30, 2025, was an outflow of $237 million, a significant decrease from an inflow of $868 million in the prior year, primarily due to Medicaid risk corridor and Marketplace risk transfer settlement activity and timing differences in government receivables and payables.
• Full-year 2025 adjusted earnings guidance was revised downwards to approximately $14.00 per diluted share, driven by higher medical cost trends across all segments, disproportionately in Marketplace.
• Implied fourth quarter 2025 adjusted earnings are expected to be approximately $0.35 per diluted share, with significant losses anticipated from Medicare and Marketplace.
• Cash and investments at the parent company decreased significantly to $108 million as of September 30, 2025, from $445 million as of December 31, 2024.

Risks

• Continued high medical cost trends across all segments, particularly in the Marketplace business, which are expected to persist through the end of 2025.
• High levels of utilization in Medicaid, Medicare (especially for high-acuity members, long-term services and supports, and pharmacy), and Marketplace segments.
• Uncertainty regarding the persistence of margin challenges, despite management's encouragement for potential improvement in 2026.
• General risks and uncertainties discussed in the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

The company raised its full-year 2025 premium revenue guidance to approximately $42.5 billion but revised its full-year 2025 adjusted earnings guidance downwards to approximately $14.00 per diluted share due to higher medical cost trends, particularly in the Marketplace segment. For the fourth quarter of 2025, implied adjusted earnings are expected to be approximately $0.35 per diluted share, with Medicaid contributing a gain offset by anticipated losses from Medicare and Marketplace. The preliminary 2026 outlook for adjusted earnings per share is expected to approximate the full year 2025 guidance, with reduced exposure to Marketplace and segment earnings at least break-even.

Management Comments

• "Our Medicaid business continues to perform well in a challenging medical cost trend environment." Joseph Zubretsky, President and Chief Executive Officer.
• "The headline for the quarter is that approximately half of our underperformance is driven by the Marketplace business, and that Medicaid, while experiencing some pressure, is producing strong margins." Joseph Zubretsky, President and Chief Executive Officer.
• "We continue to grow, we believe the margin challenges will not persist, and we are encouraged by the margin improvement potential in 2026." Joseph Zubretsky, President and Chief Executive Officer.

Industry Context

The filing highlights a "challenging medical cost trend environment" and "continued high levels of utilization," which are prevalent themes across the healthcare industry, particularly for managed care organizations dealing with government programs (Medicaid, Medicare) and the individual insurance marketplace. The disproportionate impact on the Marketplace business due to utilization relative to risk adjustment revenue suggests specific challenges within that segment, possibly related to adverse selection or inadequate pricing in the current regulatory framework.

Legal Proceedings

• Non-recurring litigation costs were incurred, impacting adjusted net income, but no specific legal proceedings were detailed in the filing.

Stakeholder Impact

• Shareholders: Negative impact due to significant decline in EPS, downward revision of guidance, and negative operating cash flow. Potential for future improvement cited for 2026.
• Customers (Members): Continued growth in membership suggests ongoing service provision, but higher utilization rates could imply increased demand for services.
• Creditors: Long-term debt increased from $2,923 million (Dec 31, 2024) to $3,664 million (Sept 30, 2025). Cash and investments at the parent company decreased, and operating cash flow was negative, which could be a concern for creditors.

Next Steps

• Management will host a conference call and webcast on October 23, 2025, to discuss the third quarter results.
• The company expects to provide formal 2026 guidance on its fourth quarter and fiscal year 2025 earnings call.
• The company will file its Quarterly Report on Form 10-Q for the period ended September 30, 2025, with the SEC.

Key Dates

Recommendation

The significant year-over-year decline in GAAP and adjusted net income, coupled with a substantial increase in the Medical Care Ratio (MCR) across all segments, particularly the Marketplace, indicates deteriorating profitability and operational efficiency. The negative operating cash flow for the nine months and the sharp reduction in parent company cash are concerning. The downward revision of full-year 2025 adjusted EPS guidance and the very low implied Q4 2025 adjusted EPS suggest that the challenges are expected to persist in the near term. While management expresses optimism for 2026, the preliminary outlook only approximates 2025 guidance, which itself has been revised downwards. These factors point to significant headwinds and a likely negative impact on the stock price.

Keywords

Molina Healthcare, MOH, Q3 2025 earnings, financial results, guidance revision, Medicaid, Medicare, Marketplace, medical care ratio, MCR, healthcare services, managed care, adjusted EPS, premium revenue, operating cash flow, utilization, risk adjustment